December 4, 2017 10:41 AM ESTUpdated December 5, 08:28 AM

Venter quickly grabs the reins back at Human Longevity; Peter Thiel backs upstart ChemomAb

Brittany Meiling

→ After less than a year in the role, Cynthia Collins is out at Human Longevity. J. Craig Venter’s high-flying anti-aging startup recruited the former …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Venter quickly grabs the reins back at Human Longevity; Peter Thiel backs upstart ChemomAb

Brittany Meiling

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?

Ven­ter quick­ly grabs the reins back at Hu­man Longevi­ty; Pe­ter Thiel backs up­start ChemomAb

Brittany Meiling

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Venter quickly grabs the reins back at Human Longevity; Peter Thiel backs upstart ChemomAb

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

Are programs with compounded GLP-1s safe for your population?